

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County - As Iowa goes blue, incoming Gov. Rob Sand and Sen. Josh Turek offer plans to address the state’s “cancer crisis”
- Anthony El-Khoueiry named director of USC Norris
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus











